The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and experimental models. We examined whether these beneficial effects can also be achieved in a non-diabetic hypertensive model, namely in Ren-2 transgenic rats (TGR). Adult 6-month-old hypertensive TGR and their normotensive controls (Hannover Sprague-Dawley rats), were either untreated or treated with empagliflozin (10 mg/kg/day) for two months. Telemetric blood pressure monitoring, renal parameters as well as cardiac function via echocardiography were analyzed during the experiment. At the end of the study, the contribution of major vasoactive systems to blood pressure maintenance was studied. Metabolic parameters and markers of oxidative stress and inflammation were also analyzed. Empagliflozin had no effect on plasma glucose level but partially reduced blood pressure in TGR. Although food consumption was substantially higher in empagliflozin-treated TGR compared to the untreated animals, their body weight and the amount of epididymal and perirenal fat was decreased. Empagliflozin had no effect on proteinuria, but it decreased plasma urea, attenuated renal oxidative stress and temporarily increased urinary urea excretion. Several metabolic (hepatic triglycerides, non-esterified fatty acids, insulin) and inflammatory (TNF-α, leptin) parameters were also improved by empagliflozin treatment. By contrast, echocardiography did not reveal any effect of empagliflozin on cardiac function. In conclusion, empagliflozin exerted beneficial antihypertensive, anti-inflammatory and metabolic effects also in a non-diabetic hypertensive model.

Department of Cardio Metabolic Research Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiology Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Department of Experimental Hypertension Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Experimental Hypertension Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22011774

003      

CZ-PrNML

005      

20220506130240.0

007      

ta

008      

220425s2021 fr f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.biopha.2021.112246 $2 doi

035    __

$a (PubMed)34601191

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a fr

100    1_

$a Hojná, Silvie $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

245    10

$a Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension / $c S. Hojná, H. Rauchová, H. Malínská, I. Marková, M. Hüttl, F. Papoušek, M. Behuliak, D. Miklánková, Z. Vaňourková, J. Neckář, M. Kadlecová, P. Kujal, J. Zicha, I. Vaněčková

520    9_

$a The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and experimental models. We examined whether these beneficial effects can also be achieved in a non-diabetic hypertensive model, namely in Ren-2 transgenic rats (TGR). Adult 6-month-old hypertensive TGR and their normotensive controls (Hannover Sprague-Dawley rats), were either untreated or treated with empagliflozin (10 mg/kg/day) for two months. Telemetric blood pressure monitoring, renal parameters as well as cardiac function via echocardiography were analyzed during the experiment. At the end of the study, the contribution of major vasoactive systems to blood pressure maintenance was studied. Metabolic parameters and markers of oxidative stress and inflammation were also analyzed. Empagliflozin had no effect on plasma glucose level but partially reduced blood pressure in TGR. Although food consumption was substantially higher in empagliflozin-treated TGR compared to the untreated animals, their body weight and the amount of epididymal and perirenal fat was decreased. Empagliflozin had no effect on proteinuria, but it decreased plasma urea, attenuated renal oxidative stress and temporarily increased urinary urea excretion. Several metabolic (hepatic triglycerides, non-esterified fatty acids, insulin) and inflammatory (TNF-α, leptin) parameters were also improved by empagliflozin treatment. By contrast, echocardiography did not reveal any effect of empagliflozin on cardiac function. In conclusion, empagliflozin exerted beneficial antihypertensive, anti-inflammatory and metabolic effects also in a non-diabetic hypertensive model.

650    _2

$a adipozita $x účinky léků $7 D050154

650    _2

$a zvířata $7 D000818

650    _2

$a antiflogistika $x farmakologie $7 D000893

650    _2

$a antihypertenziva $x farmakologie $7 D000959

650    _2

$a antioxidancia $x farmakologie $7 D000975

650    _2

$a benzhydrylové sloučeniny $x farmakologie $7 D001559

650    _2

$a krevní tlak $x účinky léků $7 D001794

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a energetický metabolismus $x účinky léků $7 D004734

650    _2

$a glukosidy $x farmakologie $7 D005960

650    _2

$a hypertenze $x farmakoterapie $x genetika $x metabolismus $x patofyziologie $7 D006973

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a potkani Sprague-Dawley $7 D017207

650    _2

$a potkani transgenní $7 D055647

650    _2

$a renin $x genetika $7 D012083

650    _2

$a hmotnostní úbytek $x účinky léků $7 D015431

655    _2

$a časopisecké články $7 D016428

700    1_

$a Rauchová, Hana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Malínská, Hana $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Marková, Irena $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Hüttl, Martina $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Papoušek, František $u Department of Cardiology, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Behuliak, Michal $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Miklánková, Denisa $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Vaňourková, Zdeňka $u Department of Experimental Hypertension, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Neckář, Jan $u Department of Cardiology, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Kadlecová, Michaela $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Kujal, Petr $u Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Zicha, Josef $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Vaněčková, Ivana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: ivana.vaneckova@fgu.cas.cz

773    0_

$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 144, č. - (2021), s. 112246

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34601191 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130232 $b ABA008

999    __

$a ok $b bmc $g 1789394 $s 1162972

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 144 $c - $d 112246 $e 20211001 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486

LZP    __

$a Pubmed-20220425